LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Akcijų sąrašas・Puma Biotechnology Inc

Puma Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

7.4 -0.54

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

7.37

Max

7.68

Pagrindiniai rodikliai
By Trading Economics
Pajamos	3M 12M
Pardavimai	21M 76M
P/E Sektoriaus vid.	12.344 49.8
Pelno marža	15.633
Darbuotojai	179
EBITDA	13M 27M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-32.89% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	25M 383M
Ankstesnė atidarymo kaina	7.94
Ankstesnė uždarymo kaina	7.4

Naujienos nuotaikos

By Acuity

50%

187 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

3.07 / 3.075 Palaikymas ir pasipriešinimas

Puma Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-06 23:41; UTC

Uždarbis

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

2026-05-06 21:40; UTC

Uždarbis

Nutrien Logs Higher Profit, Sales Growth in 1Q

2026-05-06 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-05-06 23:34; UTC

Rinkos pokalbiai

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

2026-05-06 23:12; UTC

Uždarbis

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

2026-05-06 23:11; UTC

Uždarbis

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

2026-05-06 23:07; UTC

Uždarbis

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

2026-05-06 23:05; UTC

Uždarbis

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

2026-05-06 23:04; UTC

Uždarbis

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-05-06 22:25; UTC

Rinkos pokalbiai

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

2026-05-06 22:05; UTC

Rinkos pokalbiai

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

2026-05-06 21:58; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:47; UTC

Rinkos pokalbiai

Uždarbis

Costco Posts 13% Sales Growth in April -- Market Talk

2026-05-06 21:46; UTC

Uždarbis

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

2026-05-06 21:40; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:35; UTC

Rinkos pokalbiai

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

2026-05-06 21:32; UTC

Karštos akcijos

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

2026-05-06 21:29; UTC

Uždarbis

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Puma Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

-32.89% į apačią

12 mėnesių prognozė

Vidutinis 5 USD -32.89%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Puma Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Puma Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.07 / 3.075Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

187 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.